WORLD PEPTIDEFOUNDATION

Where is Exenatide being studied?

Find registered human studies, phases, products, recruitment status and reported research locations around the world. Registry search matches are separate from this profile’s reviewed evidence.

Find studies for Exenatide →Worldwide registry directory

Scientific intelligence record

Experience 2.0

GLP-1 receptor agonist

Exenatide

Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. WPF organizes its research by formulation, type 2 diabetes outcomes, comparative studies, safety and tolerability, and other investigated questions. Formulation and dosing schedules differ across studies, so results from one preparation or population should not automatically be generalized to another.

Record status

Traceability partial

Last meaningful update: 9/26/2026

Evidence searched through:
Not recorded
Assessment updated:
9/26/2026
Documented human review:
No documented human review recorded
Automated scientific assessment:
None recorded
AI source check:
9/26/2026

Published source links and profile text pass separate gates. Only a documented human review is labelled as human review; an automated scientific assessment applies deterministic checks, and an AI source check confirms only that a source exists and matches its identifiers. A source count alone does not establish a review.

Evidence coverage has three distinct layers. The corpus count is a transparent screening inventory, the featured set contains study-level tiering and interpretation, and the published-source count contains records promoted through the institutional publication workflow. Source validation, editorial publication, and scientific appraisal are separate decisions; these numbers must not be merged.

Ranked research corpus

500

Categorized publications with provisional ranking; scientific review remains separate.

Featured tiered studies

105

Cornerstone publications with study-level interpretation, limitations, and tier disclosure.

Research domains

12

Clinical and scientific questions synthesized independently across the evidence atlas.

Published source records

5

Database records promoted through the governed publication workflow—not the corpus total.

Corpus generated 2026-09-18. Counts remain separately labeled so screening is not represented as completed review.

Human experience · separate evidence stream

No community pattern is displayed yet

Eligible observations remain below the privacy and reliability threshold. WPF will not convert a handful of reports into a percentage, trend, or clinical claim.

Observation is valuable human context. It is not evidence of causation, efficacy, or safety.

Public display gate

n ≥ 20 eligible observations

Exact progress remains private before the threshold.

Contribute an observationArchive details

Intelligence snapshot

The state of the record

A compact view of what is represented, what remains unresolved, and how completely the record can be traced.

Ranked research corpus

500

Categorized screening records; proposed rankings remain pending human appraisal.

Featured tiered studies

105

Cornerstone studies with published study-level interpretation and tier disclosure.

Research domains

12

Independent evidence dossiers covering the major research questions.

Published source records

5

Source records published through the governed workflow; this count does not certify scientific conclusions.

Contradictions

0

Conflicting evidence relationships that remain visible.

Research gaps

2

Questions the current record identifies as unresolved.

Connected media

0

Media records explicitly linked to this scientific record.

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

12 published domain syntheses connected to 105 featured studies

Exenatide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded synthesis, confidence level, evidence context, limitations, geographic applicability, regulatory interpretation, and research gaps. Publication of these syntheses is separate from the scientific review status shown above.

Inspect the reconciled evidence atlas
Inspect the published evidence record5 governed records · titles, provenance, and original-source linksOpen records ↓
Insufficient evidence

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Source reference associated with Exenatide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.2337/dc17-0417
PubMed
29246950
Open original source
Insufficient evidence

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Source reference associated with Exenatide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1056/nejmoa1612917
PubMed
28910237
Open original source
Insufficient evidence

Exenatide.

Source reference associated with Exenatide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1517/14656566.8.15.2593
PubMed
17931093
Open original source
Insufficient evidence

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.

Source reference associated with Exenatide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1172/jci.insight.159863
PubMed
36066977
Open original source
Insufficient evidence

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

Source reference associated with Exenatide. Source identity and peptide connection confirmed; scientific conclusions and evidence strength have not been assessed in this source-linking step.

Source
other
DOI
10.1016/s0140-6736(17)31585-4
PubMed
28781108
Open original source

Scientific context

Chemistry and represented biological context

Existing reviewed chemistry is preserved as scientific context. Chemistry and mechanism information do not establish clinical efficacy or safety.

Open chemistry and biological context ↓
Chemical identity

Chemistry has not yet been reviewed

No reviewed chemical identity record is currently available for this entry. This is an information-state limitation, not evidence that chemical information does not exist elsewhere.

Explore further

Continue through the research system

Move from this peptide record into the project's broader evidence, research, comparison, and methodology systems.

Research discovery

Compare peptides

Examine represented peptide records side by side.

Evidence system

Explore how scientific evidence is represented and reviewed.

Research hub

Enter the broader research and intelligence environment.

Methodology

Review project methods, boundaries, and interpretation rules.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

  1. Date unavailable · study · Temporal status not established

    Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

    other

  2. Date unavailable · study · Temporal status not established

    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

    other

  3. Date unavailable · study · Temporal status not established

    Exenatide.

    other

  4. Date unavailable · study · Temporal status not established

    Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.

    other

  5. Date unavailable · study · Temporal status not established

    Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

    other

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Chemistry coverage

A reviewed chemistry record is not currently represented.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Connections

Follow the scientific relationships

Connections appear only when they are represented by the project’s underlying records.

Open 1 represented connection ↓

institution

other

represented evidence source

Traceability

Follow the record back to its source

The experience makes incomplete links visible instead of presenting a false impression of perfect provenance.

Source publication state

A governed source may be verified and approved for publication while its claim-to-evidence link is still incomplete.

Reviewer provenance state

“Human scientist reviewed: no” means that specific source-path attribution is not recorded. It does not silently negate the separate publication-review state.

Domain conclusion → Evidence

Connected

Evidence → Source

Connected

Source → Original record

Connected

Traceability documents how the project connects statements to records. It does not establish that a source is scientifically valid or that a claim is clinically true.

Reconciled for 12 domain conclusions and 105 featured studies.

Detailed study-to-domain mappings and original-source paths appear in the Exenatide evidence-governance section.

Inspect the ranked source records

Observational archive

What contributors reported

Observational archive data is intentionally separated from published scientific evidence.

Observational boundary

Insufficient eligible observations are available for display under the current filters.

Insufficient eligible observations are currently represented to display aggregated findings for this peptide.

Research + media

Media connected to this scientific record

Only media explicitly linked through the project’s relationship system appears here.

No scientifically connected media is currently represented for this peptide.

Sources + provenance

Read the scientific record with its boundaries intact

The public record organizes reviewed evidence; it does not establish scientific truth by itself.
Association, mechanism, observation and regulatory status must not be represented as proof of clinical efficacy or safety.
Observational reports describe contributor experiences and cannot establish causation, effectiveness, safety or clinical benefit.
Contradictory and qualifying evidence must remain visible rather than being silently discarded.
Absence of represented evidence is not evidence that research does not exist.
Research gaps identify unresolved questions; they are not negative conclusions.
Regulatory status is distinct from scientific evidence quality.
Media relationships provide context and explanation; they do not increase the strength of scientific evidence.
A section with no represented records is an incomplete project record, not a scientific conclusion.
Researcher and institutional relationships are shown only when supported by represented records and must not be interpreted as rankings or endorsements.

Generated: 11/8/2026, 5:24:46 PM

global evidence atlas

Exenatide research, ranked and separated by purpose

This is a deduplicated literature screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.

4,879Discoverable source universe
500Ranked screening records
12Research domains
1Governed published sources

500 matching records · ranked 2026-09-18

Page 1 of 20

Count reconciliation: 4,879 discoverable source records match the peptide identity query; 500 are retained in this bounded, ranked screening view; 1 belong to the separate governed layer labeled “Governed published sources.” Domain totals overlap because one publication may inform several questions.

Exenatide evidence · ranking key

How evidence is ranked

A tier describes the evidentiary role and design strength of a source. It is not a popularity score, proof that every conclusion is correct, or a substitute for claim-level review.

A

Practice-defining evidence

Large, well-conducted randomized trials; prespecified major outcomes; rigorous systematic reviews or meta-analyses; and major regulatory assessments.

B

Strong supporting evidence

Smaller randomized trials, strong prospective cohorts, prespecified secondary analyses, and high-quality comparative-effectiveness studies.

C

Contextual evidence

Retrospective cohorts, claims-database studies, pharmacovigilance analyses, mechanistic human research, and well-documented case series.

D

Signal-generating evidence

Case reports, conference abstracts, preclinical research, hypothesis-generating analyses, and expert commentary.

Tier and confidence answer different questions

Tier classifies source design and evidentiary role. Confidence reflects risk of bias, sample size, comparator quality, outcome relevance, follow-up, missing data, directness, replication, reporting quality, and whether conclusions stay within the measured results.

Funding and conflicts are disclosed and considered, but sponsorship never automatically changes a tier. Corrections, retractions, and expressions of concern override the original rating.

Suggested citation

  • APA

    World Peptide Foundation. (n.d.). Exenatide — Peptide Scientific Intelligence. World Peptide Foundation. (Updated September 26, 2026.) https://www.worldpeptidefoundation.org/directory/exenatide

  • AMA / Vancouver

    World Peptide Foundation. Exenatide — Peptide Scientific Intelligence. World Peptide Foundation website. Updated September 26, 2026. https://www.worldpeptidefoundation.org/directory/exenatide